



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations. Visit go.covermymeds.com/OptumRx to begin using this free service. Please note: All information below is required to process this request. Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Morphine Extended-Release [ER] Capsule (generic Avinza) Long-Acting Opioid Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information <small>(required)</small>					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information <small>(required)</small>					
<p>For states, such as GA and AR, that have a terminal illness mandate, and for patients who have a terminal illness, please answer the following:</p> <p>Will the requested medication be used for the treatment of a terminal condition or associated symptoms? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If "YES", please indicate the patient's estimated life expectancy:</p> <p><input type="checkbox"/> Less than 6 months <input type="checkbox"/> Less than 24 months <input type="checkbox"/> Less than ____ months (please specify)</p>					
<p>Continuation of therapy:</p> <p>Is the patient established on the prescribed medication and this prescription is for continuation of therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>Select all the applicable diagnoses below:</p> <p><input type="checkbox"/> Cancer pain</p> <p><input type="checkbox"/> Moderate to severe chronic pain that is non-neuropathic</p> <p><input type="checkbox"/> Moderate to severe neuropathic pain or fibromyalgia</p> <p><input type="checkbox"/> Other diagnosis: _____ <input type="checkbox"/> ICD-10 Code(s): _____</p>					
<p>End of life care:</p> <p>Is the patient receiving opioids as part of end of life care? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>					
<p>For diagnosis of moderate to severe chronic pain that is non-neuropathic, please answer the following:</p> <p>Is the prescribed medication being used as an as-needed (PRN) analgesic? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the prescribed medication being used for pain that is mild or not expected to persist for an extended period of time? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the prescribed medication being used for acute pain? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the prescribed medication being used for postoperative pain? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please answer the following:</p> <ul style="list-style-type: none"> <input type="checkbox"/> Has the patient already received chronic opioid therapy prior to surgery or is the postoperative pain expected to be moderate to severe and persist for an extended period of time? <input type="checkbox"/> Yes <input type="checkbox"/> No <p>Is the patient filling the prescribed medication for the first time? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Prior to the start of therapy with the prescribed medication, has the patient failed an adequate trial of a short-acting opioid? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please document the name of the medication(s), dose, date, and duration of trial:</p> <p>Medication: _____ Dose: _____ Date of trial: _____ Duration of trial: _____</p>					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**
Office use only: Avinza-MorphineER_Comm_2018Nov-W



Morphine Extended-Release [ER] Capsule (generic Avinza) Long-Acting Opioid Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For diagnosis of moderate to severe neuropathic pain or fibromyalgia, please answer the following:

Does the patient have a contraindication to or has not exhibited an adequate response to treatment with gabapentin titrated to a therapeutic dose? Yes No If **yes**, please document dose, date, and duration of trial:

Dose: _____ Date of trial: _____ Duration of trial: _____

Does the patient have a contraindication to or has not exhibited an adequate response to treatment with a tricyclic antidepressant titrated to a therapeutic dose? Yes No If **yes**, please document the name of the medication(s), dose, date, and duration of trial:

Medication: _____ Dose: _____ Date of trial: _____ Duration of trial: _____

Is the patient filling the prescribed medication for the first time? Yes No

Prior to the start of therapy with the prescribed medication, has the patient failed an adequate trial of a short-acting opioid? Yes No

If **yes**, please document the name of the medication(s), dose, date, and duration of trial:

Medication: _____ Dose: _____ Date of trial: _____ Duration of trial: _____

Reauthorization [Non-cancer and non-end of life care only]:

If this is a reauthorization request, please answer all of the following questions:

1. What are the treatment goals for this patient? (Document treatment goals and estimated duration of treatment) _____

2. Does the treatment plan include the use of a non-opioid analgesic and/or non-pharmacologic intervention? Yes No

3. Has the patient demonstrated meaningful improvement in pain and function using a validated instrument (e.g., Brief Pain Inventory)? Yes No

4. Has the patient been screened for substance abuse/opioid dependence using a validated instrument (e.g., DAST-10)? Yes No

5. What is the rationale for not tapering and discontinuing the requested medication? (Document rationale) _____

6. Has the patient been screened for comorbid mental health conditions? Yes No

7. Is there a state prescription drug monitoring program (PDMP) available? Yes No

If **yes**, has the prescriber identified that there are NO concurrently prescribed controlled substances from the PDMP? Yes No

8. Does the prescriber acknowledge that he/she has completed an assessment of increased risk for respiratory depression in patients who have medical comorbidities or are using concurrent benzodiazepine/other drugs that could potentially cause drug-drug interactions? Yes No

9. What is the patient's total daily morphine equivalent dose? _____

Quantity limit requests:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

Titration or loading-dose purposes

Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

Requested strength/dose is not commercially available

Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.

For urgent or expedited requests please call 1-800-711-4555.

This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**
Office use only: Avinza-MorphineER_Comm_2018Nov-W